Evidence map›Paper›PMID 40200648›Full record

Trial reportClinical and translational science2025

Clinical Evaluation of the Effect of Aficamten on QT/QTc Interval in Healthy Participants.

Neha Maharao, Donghong Xu, Tyrell J Simkins, Owen Bowles, Genzhou Liu, Youcef Benattia, Adrienne Griffith, Stephen B Heitner, Stuart Kupfer, Polina German

Abstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Clinical and translational science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Neha MaharaoDepartment of Clinical Pharmacology, Cytokinetics, Incorporated, South San Francisco, California, USA.
Donghong XuDepartment of Clinical Pharmacology, Cytokinetics, Incorporated, South San Francisco, California, USA.ORCID 0009-0000-9678-0133
Tyrell J SimkinsDepartment of Clinical Research, Cytokinetics, Incorporated, South San Francisco, California, USA.
Owen BowlesDepartment of Clinical Operations, Cytokinetics, Incorporated, South San Francisco, California, USA.
Genzhou LiuDepartment of Biostatistics, Cytokinetics, Incorporated, South San Francisco, California, USA.
Youcef BenattiaDepartment of Drug Safety and Pharmacovigilance, Cytokinetics, Incorporated, South San Francisco, California, USA.
Adrienne GriffithDepartment of Clinical Pharmacology, Cytokinetics, Incorporated, South San Francisco, California, USA.
Stephen B HeitnerDepartment of Clinical Research, Cytokinetics, Incorporated, South San Francisco, California, USA.
Stuart KupferDepartment of Clinical Research, Cytokinetics, Incorporated, South San Francisco, California, USA.
Polina GermanDepartment of Clinical Pharmacology, Cytokinetics, Incorporated, South San Francisco, California, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Aficamten is a next-in-class, small-molecule, cardiac myosin inhibitor in development for treating hypertrophic cardiomyopathy (HCM). This 2-part study evaluated aficamten's impact on QTc interval in healthy participants. Part A (n = 10) was an open-label study to find the appropriate dose for thorough QT (TQT) evaluation in Part B. Part B (n = 34) was a double-blind, 3-way crossover TQT study conducted as per ICH E14 guidance using negative (placebo) and positive (moxifloxacin) controls. A single 50 mg aficamten dose achieved exposures (C

Indexed as

ElectrocardiographyHeart RateLong QT SyndromePyrazolesAdultCross-Over StudiesDose-Response Relationship, DrugDouble-Blind MethodFemaleHealthy VolunteersHumansMaleMiddle AgedMoxifloxacinYoung AdultaficamtenMoxifloxacinPyrazolescardiovascular diseasephase 1QTQTc intervalsafety

Identifiers

PMID40200648
PMCPMC11979292

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.